Related Experiment Video
Updated: Jul 5, 2025
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
Xiu Chen1,2, Liqiu Kou1,2, Xiaolu Xie1,2
1Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Abstract:
The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of cancer therapy in recent years, which have changed the landscape of cancer treatment. In the field of HCC treatment, this class of drugs has shown good therapeutic prospects. For example, atezolizumab in combination with bevacizumab has been approved as first-line treatment for advanced HCC due to significant efficacy. However, sensitivity to ICI therapy varies widely among HCC patients. Therefore, there is an urgent need to search for determinants of resistance/sensitivity to ICIs and to screen biomarkers that can predict the efficacy of ICIs. This manuscript reviews the research progress of prognostic biomarkers associated with ICIs in HCC in order to provide a scientific basis for the development of clinically individualised precision medication regimens.
Insights
Immune checkpoint inhibitors (ICIs) show promise for advanced hepatocellular carcinoma (HCC). Identifying biomarkers predicting patient response to ICI therapy is crucial for personalized treatment strategies in HCC.
Area of Science:
- Hepatobiliary Cancers
- Immunotherapy
- Oncology
Background:
- Advanced hepatocellular carcinoma (HCC) presents significant treatment challenges.
- Immune checkpoint inhibitors (ICIs) have emerged as a transformative therapy in oncology.
- Current ICI treatments for HCC, like atezolizumab plus bevacizumab, show efficacy but patient response varies.
Purpose of the Study:
- To review prognostic biomarkers associated with ICI therapy in HCC.
- To identify determinants of resistance and sensitivity to ICIs in HCC patients.
- To provide a basis for developing personalized precision medicine regimens for HCC.
Main Methods:
- Literature review of research on prognostic biomarkers for ICI therapy in HCC.
- Analysis of studies investigating patient sensitivity and resistance to ICIs.
- Synthesis of findings to guide clinical decision-making.
Main Results:
- Significant variability exists in HCC patient responses to ICI therapy.
- Biomarkers are essential for predicting ICI efficacy and guiding treatment selection.
- Ongoing research aims to uncover reliable prognostic markers for HCC immunotherapy.
Conclusions:
- Predictive biomarkers are critical for optimizing ICI therapy in advanced HCC.
- Further research into biomarkers will enable individualized treatment strategies.
- Understanding ICI response determinants is key to improving HCC patient outcomes.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021